Company Overview of AnaptysBio, Inc.
AnaptysBio, Inc. focuses on the generation of antibody therapeutics, as well as on the use of somatic hypermutation (SHM) for antibody discovery and optimization. The company’s SHM-XEL platform couples human antibody libraries with in vitro somatic hypermutation in mammalian cells to generate high affinity antibodies that replicates key features of the human immune system. It develops ANB020Its, an anti-IL-33 lead candidate antibody that inhibits IL-33 cytokine function by blocking interaction with receptor at low picomolar potency; a portfolio of antibodies for immuno-oncology to modulate the function of T cell negative regulators, including PD-1, TIM-3, and LAG-3; ANB012, an anti-ActRIIb a...
10421 Pacific Center Court
San Diego, CA 92121
Founded in 2005
Key Executives for AnaptysBio, Inc.
Chief Development Officer
Compensation as of Fiscal Year 2014.
AnaptysBio, Inc. Key Developments
TESARO and AnaptysBio Expand Immuno-Oncology Collaboration to Include Novel Bispecific Antibody Candidate
Dec 2 14
TESARO, Inc. and AnaptysBio, Inc. announced an expansion of their immuno-oncology collaboration and exclusive license agreement to include development of a novel bispecific antibody candidate designed to target two undisclosed immune checkpoints. Under the terms of this expansion, TESARO will pay AnaptysBio an undisclosed upfront fee and will provide funding for all costs incurred by AnaptysBio related to the development of a clinical antibody candidate. For each program within the collaboration, AnaptysBio is eligible to receive milestone payments if certain research and development events are achieved and additional payments for achievement of certain U.S. and ex-U.S. regulatory submissions and approvals in multiple indications. AnaptysBio will also be eligible to receive royalties related to worldwide net sales of products developed under the collaboration, and may earn certain commercial milestone payments if specified levels of annual worldwide net sales are attained. AnaptysBio and TESARO will together complete preclinical development of the antibody candidates, with TESARO being solely responsible for all clinical development, manufacturing, regulatory and commercial activities.
AnaptysBio, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-13-2014 01:30 PM
Nov 9 14
AnaptysBio, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-13-2014 01:30 PM. Venue: Apella, 450 East 29th Street, New York, New York, United States. Speakers: Hamza Suria, Chief Executive Officer, President and Director.
AnaptysBio, Inc. Appoints Marco Londei as Chief Development Officer
Oct 20 14
AnaptysBio, Inc. announced the appointment of Marco Londei, M.D. as Chief Development Officer. Dr. Londei will lead the preclinical and clinical development of AnaptysBio's proprietary antibody pipeline. Dr. Londei joins AnaptysBio from Bristol-Myers Squibb (BMS) where he was Therapeutic Area Head, Immunosciences and responsible for early clinical and translational research for a portfolio of immune-related therapeutics.
Similar Private Companies By Industry
Recent Private Companies Transactions